Form 4: Penumbra Director Wilder Acquires RSUs Amid Merger Talk

Penumbra Director Thomas Wilder acquired 589 restricted stock units, subject to a vesting schedule and potential accelerated vesting upon a merger with Boston Scientific.

Summary

• Thomas Wilder, a Director of Penumbra Inc. (PEN), acquired 589 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for the RSU acquisition was February 13, 2026.
• These RSUs vest in four equal installments: 1/4 on March 31, 2026, 1/4 on June 30, 2026, 1/4 on September 30, 2026, and 1/4 on December 31, 2026, contingent on Mr. Wilder's continued service as director through such dates.
• Full vesting will occur upon the "Closing" of the merger agreement dated January 14, 2026, among Penumbra, Boston Scientific Corporation, and Pinehurst Merger Sub, Inc., provided Mr. Wilder remains a director.
• Mr. Wilder also indirectly beneficially owns 4,506 shares of Common Stock through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reports a routine RSU grant to a director, with the added context of a potential merger that could accelerate vesting, which is generally seen as a positive for director alignment.

Positives

• Director Thomas Wilder acquired 589 Restricted Stock Units (RSUs) in Penumbra Inc., aligning his interests with shareholder value.
• The RSUs include a provision for accelerated vesting upon the closing of the merger with Boston Scientific Corporation, indicating a potential near-term liquidity event for the director and a clear incentive structure related to the merger.

Future Outlook

The filing indicates a potential future merger with Boston Scientific Corporation, which, if it closes, would trigger accelerated vesting of the director's restricted stock units, suggesting a significant corporate event on the horizon for Penumbra.

Industry Context

StockSavvy.ai notes that insider transactions, particularly RSU grants, are common forms of equity compensation for directors in the medical device industry. The explicit mention of a merger with Boston Scientific Corporation suggests potential consolidation or strategic shifts within the sector, which could significantly impact Penumbra's market position and future trajectory.

Comparison to Industry Standards

• The RSU grant structure with a service-based vesting schedule is a common compensation practice for non-employee directors across various industries, including medical devices.
• The accelerated vesting clause tied to a merger event is a standard provision in change-of-control agreements, designed to align director incentives with shareholder interests during an acquisition, consistent with practices seen in similar M&A scenarios within the healthcare sector.

Related Party Transactions

• Thomas Wilder's indirect beneficial ownership of 4,506 shares is held by the Thomas and Catharine Wilder Family Trust dated March 31, 2006.

Stakeholder Impact

• Shareholders: The RSU grant aligns director incentives with shareholder value, particularly with the merger clause. The potential merger itself would have a significant impact on shareholder value.
• Director (Thomas Wilder): Receives equity compensation, subject to continued service and potential accelerated vesting upon a merger event.

Next Steps

• Continued service of Thomas Wilder as a director through the specified vesting dates.
• Potential closing of the merger with Boston Scientific Corporation, which would trigger accelerated RSU vesting.

Key Dates

Keywords

Penumbra, PEN, Thomas Wilder, Director, RSU, Restricted Stock Units, Insider Transaction, Form 4, Boston Scientific, Merger